Open Access

Novel compound cedrelone inhibits hepatocellular carcinoma progression via PBLD and Ras/Rap1

  • Authors:
    • Jiansong Wu
    • Qiang Niu
    • Jie Yuan
    • Xiaodan Xu
    • Liuxia Cao
  • View Affiliations

  • Published online on: October 7, 2019     https://doi.org/10.3892/etm.2019.8080
  • Pages: 4209-4220
  • Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Although it is known that Phenazine biosynthesis‑like domain‑containing protein (PBLD) expression is downregulated in hepatocellular carcinoma (HCC), its biological function is unclear. Additionally, no agents capable of upregulating PBLD exist. In the current study, the relationship between PBLD and HCC was analyzed using clinicopathological specimens. A HCC cell model, microarray analysis and an animal model were used to verify the therapeutic effect of cedrelone on HCC. The present study demonstrated that PBLD inhibited HCC progression. Furthermore, the present study revealed that cedrelone possessed treated‑HCC capabilities via targeted PBLD overexpression. The epithelial‑mesenchymal transition phenotype and growth rate were inhibited and the apoptosis ratio was promoted by cedrelone following PBLD overexpression. The Ras and Ras‑proximate‑1 signaling pathways were also determined to be regulated by cedrelone via PBLD activation in HCC. PBLD may therefore be an independent predictor of HCC progression and a novel target for HCC treatment. Additionally, the PBLD activator, cedrelone, may be a potential drug for HCC treatment in the future.
View Figures
View References

Related Articles

Journal Cover

December 2019
Volume 18 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Wu, J., Niu, Q., Yuan, J., Xu, X., & Cao, L. (2019). Novel compound cedrelone inhibits hepatocellular carcinoma progression via PBLD and Ras/Rap1 . Experimental and Therapeutic Medicine, 18, 4209-4220. https://doi.org/10.3892/etm.2019.8080
MLA
Wu, J., Niu, Q., Yuan, J., Xu, X., Cao, L."Novel compound cedrelone inhibits hepatocellular carcinoma progression via PBLD and Ras/Rap1 ". Experimental and Therapeutic Medicine 18.6 (2019): 4209-4220.
Chicago
Wu, J., Niu, Q., Yuan, J., Xu, X., Cao, L."Novel compound cedrelone inhibits hepatocellular carcinoma progression via PBLD and Ras/Rap1 ". Experimental and Therapeutic Medicine 18, no. 6 (2019): 4209-4220. https://doi.org/10.3892/etm.2019.8080